PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.82%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-4.34%
G&A reduction while GNPX shows 48.62% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine efficiency.
-6.85%
Operating expenses reduction while GNPX shows 24.13% growth. Joel Greenblatt would examine advantage.
-6.85%
Total costs reduction while GNPX shows 24.13% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
4.17%
Similar D&A growth to GNPX's 5.19%. Walter Schloss would investigate industry patterns.
16.91%
EBITDA growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Operating income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-5.45%
Other expenses reduction while GNPX shows 47.47% growth. Joel Greenblatt would examine advantage.
16.61%
Pre-tax income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
16.61%
Net income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
17.14%
EPS growth while GNPX declines. John Neff would investigate advantages.
17.14%
Diluted EPS growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.